4th Annual Immune Checkpoint Inhibitors (ICI) Boston Summit
In-Person Event
Mar 19 - 21, 2018
Boston, Massachusetts, USA
OVERVIEW
4th Annual Immune Checkpoint Inhibitors (ICI) Boston Summit is organized by Hanson Wade and will be held during Mar 19 - 21, 2018 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America. The target audience for this medical event is immunologists.
Rather than attempting to cover the entire IO space and only providing superficial insights, this conference has the focus required to drill down into the real details. Discover how to overcome key preclinical, translational and clinical drug development challenges encountered in the development of checkpoint modulators.
This Conference will unite industry leaders including Merck, BMS, Genentech and Novartis to share in-depth case studies on topics such as overcoming resistance to checkpoint blockade, identifying translational biomarkers and understanding the mechanistic rationale behind combination strategies.
Join leading drug developers who have successfully developed IO therapeutics and ensure you make the right decisions with your IO pipeline.
Course Topics :
• Investigating and overcoming mechanisms of resistance to checkpoint modulation
• Identifying more predictive preclinical models able to translate combination immunotherapies to the clinic more effectively
• Understanding and learning from the rationale behind successful combination strategies
• Selecting relevant translational biomarkers to ensure clinical development is robust
• Learning from emerging clinical trial data and using these insights to make informed decisions early in the development pathway
Please note: earlybird discounts are available. Secure your place early for maximum savings. Visit the event website for full details on discounts.
Prices:
Standard Rate - Conference + 2 Workshops: USD 3997,
Standard Rate - Conference + 1 Workshop: USD 3398,
Standard Rate - Conference Only: USD 2799,
Standard Rate - Workshop Only: USD 699.
Speakers: Roger Dansey (Merck), Israel Lowy (Regeneron), Corinne Reimer (AstraZeneca), Bernard Fox (Providence Cancer Center), Bill Grossman (Genentech), Amy Peterson (BeiGene), Lata Jayaraman (Seres Therapeutics), Jochem Gokemeijer (Bristol-Myers Squibb), Catherine Sabatos-Peyton (Novartis).
Additional details will be posted as soon as they are available.
Rather than attempting to cover the entire IO space and only providing superficial insights, this conference has the focus required to drill down into the real details. Discover how to overcome key preclinical, translational and clinical drug development challenges encountered in the development of checkpoint modulators.
This Conference will unite industry leaders including Merck, BMS, Genentech and Novartis to share in-depth case studies on topics such as overcoming resistance to checkpoint blockade, identifying translational biomarkers and understanding the mechanistic rationale behind combination strategies.
Join leading drug developers who have successfully developed IO therapeutics and ensure you make the right decisions with your IO pipeline.
Course Topics :
• Investigating and overcoming mechanisms of resistance to checkpoint modulation
• Identifying more predictive preclinical models able to translate combination immunotherapies to the clinic more effectively
• Understanding and learning from the rationale behind successful combination strategies
• Selecting relevant translational biomarkers to ensure clinical development is robust
• Learning from emerging clinical trial data and using these insights to make informed decisions early in the development pathway
Please note: earlybird discounts are available. Secure your place early for maximum savings. Visit the event website for full details on discounts.
Prices:
Standard Rate - Conference + 2 Workshops: USD 3997,
Standard Rate - Conference + 1 Workshop: USD 3398,
Standard Rate - Conference Only: USD 2799,
Standard Rate - Workshop Only: USD 699.
Speakers: Roger Dansey (Merck), Israel Lowy (Regeneron), Corinne Reimer (AstraZeneca), Bernard Fox (Providence Cancer Center), Bill Grossman (Genentech), Amy Peterson (BeiGene), Lata Jayaraman (Seres Therapeutics), Jochem Gokemeijer (Bristol-Myers Squibb), Catherine Sabatos-Peyton (Novartis).
Additional details will be posted as soon as they are available.
KEY DATES
19 Mar, 2018
Event Start Date
21 Mar, 2018
Event End Date
SPECIALITIES
Immunology and MicrobiologySUGGESTED HOTELS
CONFERENCE VENUE
Revere Hotel Boston CommonRELATED CONFERENCES & LIVE WEBINARS
Quick Links